{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:07:27Z","timestamp":1791331647838,"version":"4.3.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>BLyS, recently shown to be critical for survival of normal B cells, has been found to be elevated in a number of immune disease models. A role for BLyS in the survival of malignant B cells has also been revealed and we therefore sought to identify a role for BLyS and its receptors in non-Hodgkin lymphoma (NHL). We found that tumor cells from all NHL histologic subtypes expressed one or more of 3 known receptors (BCMA, TACI, and BAFF-R) for BLyS; however, the pattern of expression was variable. We provide evidence that BLyS is expressed in tumors from patients with NHL and that BLyS levels increase as tumors transform to a more aggressive phenotype. Additionally, we provide evidence that serum BLyS levels are elevated in a subgroup of patients with NHL. In patients with de novo large B-cell lymphoma, a high BLyS level correlated with a poorer median overall survival, the presence of constitutional symptoms, and elevated values of lactic dehydrogenase. When BLyS levels were correlated with response to therapy in all patients, responding patients had a significantly lower BLyS level than those with progressive disease. In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma.<\/jats:p>","DOI":"10.1182\/blood-2004-02-0762","type":"journal-article","created":{"date-parts":[[2004,7,14]],"date-time":"2004-07-14T00:26:40Z","timestamp":1089764800000},"page":"2247-2253","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":209,"title":["Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome"],"prefix":"10.1182","volume":"104","author":[{"given":"Anne J.","family":"Novak","sequence":"first","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna M.","family":"Grote","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Stenson","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Ziesmer","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Harder","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay M.","family":"Ristow","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Bram","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Jelinek","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"Gross","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"From the Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN; and ZymoGenetics, Seattle WA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021219435664400_REF1","doi-asserted-by":"crossref","unstructured":"Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104: 487-501.","DOI":"10.1016\/S0092-8674(01)00237-9"},{"key":"2020021219435664400_REF2","doi-asserted-by":"crossref","unstructured":"Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21: 231-264.","DOI":"10.1146\/annurev.immunol.21.120601.141152"},{"key":"2020021219435664400_REF3","doi-asserted-by":"crossref","unstructured":"Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998; 188: 1185-1190.","DOI":"10.1084\/jem.188.6.1185"},{"key":"2020021219435664400_REF4","doi-asserted-by":"crossref","unstructured":"Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189: 1747-1756.","DOI":"10.1084\/jem.189.11.1747"},{"key":"2020021219435664400_REF5","doi-asserted-by":"crossref","unstructured":"Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190: 1697-1710.","DOI":"10.1084\/jem.190.11.1697"},{"key":"2020021219435664400_REF6","doi-asserted-by":"crossref","unstructured":"Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404: 995-999.","DOI":"10.1038\/35010115"},{"key":"2020021219435664400_REF7","doi-asserted-by":"crossref","unstructured":"Groom J, Kalled SL, Cutler AH, et al. Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest. 2002;109: 59-68.","DOI":"10.1172\/JCI0214121"},{"key":"2020021219435664400_REF8","doi-asserted-by":"crossref","unstructured":"Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997;90: 766-775.","DOI":"10.1182\/blood.V90.2.766"},{"key":"2020021219435664400_REF9","doi-asserted-by":"crossref","unstructured":"Zulman J, Jaffe R, Talal N. Evidence that the malignant lymphoma of Sjogren's syndrome is a monoclonal B-cell neoplasm. N Engl J Med. 1978;299: 1215-1220.","DOI":"10.1056\/NEJM197811302992204"},{"key":"2020021219435664400_REF10","doi-asserted-by":"crossref","unstructured":"Batten M, Fletcher C, Ng LG, et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol. 2004;172: 812-822.","DOI":"10.4049\/jimmunol.172.2.812"},{"key":"2020021219435664400_REF11","doi-asserted-by":"crossref","unstructured":"Madry C, Laabi Y, Callebaut I, et al. The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int Immunol. 1998;10: 1693-1702.","DOI":"10.1093\/intimm\/10.11.1693"},{"key":"2020021219435664400_REF12","doi-asserted-by":"crossref","unstructured":"von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science. 1997;278: 138-141.","DOI":"10.1126\/science.278.5335.138"},{"key":"2020021219435664400_REF13","doi-asserted-by":"crossref","unstructured":"Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293: 2108-2111.","DOI":"10.1126\/science.1061965"},{"key":"2020021219435664400_REF14","doi-asserted-by":"crossref","unstructured":"Yan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 2001;11: 1547-1552.","DOI":"10.1016\/S0960-9822(01)00481-X"},{"key":"2020021219435664400_REF15","doi-asserted-by":"crossref","unstructured":"Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15: 289-302.","DOI":"10.1016\/S1074-7613(01)00183-2"},{"key":"2020021219435664400_REF16","doi-asserted-by":"crossref","unstructured":"Yan M, Wang H, Chan B, et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol. 2001;2: 638-643.","DOI":"10.1038\/89790"},{"key":"2020021219435664400_REF17","doi-asserted-by":"crossref","unstructured":"von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity. 2001;14: 573-582.","DOI":"10.1016\/S1074-7613(01)00130-3"},{"key":"2020021219435664400_REF18","doi-asserted-by":"crossref","unstructured":"Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity. 2003; 18: 279-288.","DOI":"10.1016\/S1074-7613(03)00025-6"},{"key":"2020021219435664400_REF19","doi-asserted-by":"crossref","unstructured":"Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103: 689-694.","DOI":"10.1182\/blood-2003-06-2043"},{"key":"2020021219435664400_REF20","doi-asserted-by":"crossref","unstructured":"Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J Jr. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood. 2003;102: 592-600.","DOI":"10.1182\/blood-2002-10-3161"},{"key":"2020021219435664400_REF21","doi-asserted-by":"crossref","unstructured":"Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003;112: 286-297.","DOI":"10.1172\/JCI18025"},{"key":"2020021219435664400_REF22","doi-asserted-by":"crossref","unstructured":"Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2: 465-475.","DOI":"10.1038\/nri844"},{"key":"2020021219435664400_REF23","doi-asserted-by":"crossref","unstructured":"Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood. 2002;100: 2973-2979.","DOI":"10.1182\/blood-2002-02-0558"},{"key":"2020021219435664400_REF24","doi-asserted-by":"crossref","unstructured":"Briones J, Timmerman JM, Hilbert DM, Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol. 2002;30: 135-141.","DOI":"10.1016\/S0301-472X(01)00774-3"},{"key":"2020021219435664400_REF25","doi-asserted-by":"crossref","unstructured":"Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285: 260-263.","DOI":"10.1126\/science.285.5425.260"},{"key":"2020021219435664400_REF26","doi-asserted-by":"crossref","unstructured":"Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192: 953-964.","DOI":"10.1084\/jem.192.7.953"},{"key":"2020021219435664400_REF27","doi-asserted-by":"crossref","unstructured":"Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103: 3148-3157.","DOI":"10.1182\/blood-2003-06-1984"},{"key":"2020021219435664400_REF28","doi-asserted-by":"crossref","unstructured":"Kern C, Cornuel JF, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood. 2004;103: 679-688.","DOI":"10.1182\/blood-2003-02-0540"},{"key":"2020021219435664400_REF29","doi-asserted-by":"crossref","unstructured":"Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001;97: 198-204.","DOI":"10.1182\/blood.V97.1.198"},{"key":"2020021219435664400_REF30","doi-asserted-by":"crossref","unstructured":"Scapini P, Nardelli B, Nadali G, et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med. 2003;197: 297-302.","DOI":"10.1084\/jem.20021343"},{"key":"2020021219435664400_REF31","doi-asserted-by":"crossref","unstructured":"Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med. 2003;198: 937-945.","DOI":"10.1084\/jem.20030789"},{"key":"2020021219435664400_REF32","doi-asserted-by":"crossref","unstructured":"Keating MJ, Messmer B, Damle RN, et al. Biology and treatment of chronic lymphocytic leukemia. Hematology (Amer Soc Hematol Educ Program). 2003;2003: 153-175.","DOI":"10.1182\/asheducation-2003.1.153"},{"key":"2020021219435664400_REF33","doi-asserted-by":"crossref","unstructured":"He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF\/BLyS and APRIL. J Immunol. 2004;172: 3268-3279.","DOI":"10.4049\/jimmunol.172.5.3268"},{"key":"2020021219435664400_REF34","doi-asserted-by":"crossref","unstructured":"Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis. 2003;62: 168-171.","DOI":"10.1136\/ard.62.2.168"},{"key":"2020021219435664400_REF35","doi-asserted-by":"crossref","unstructured":"Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44: 1313-1319.","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S"},{"key":"2020021219435664400_REF36","doi-asserted-by":"crossref","unstructured":"Craxton A, Magaletti D, Ryan EJ, Clark EA. Macrophage- and dendritic cell\u2013dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood. 2003;101: 4464-4471.","DOI":"10.1182\/blood-2002-10-3123"},{"key":"2020021219435664400_REF37","doi-asserted-by":"crossref","unstructured":"Stohl W. B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep. 2002;4: 345-350.","DOI":"10.1007\/s11926-002-0044-7"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/8\/2247\/1702280\/zh802004002247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/8\/2247\/1702280\/zh802004002247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T01:16:06Z","timestamp":1581556566000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/8\/2247\/19066\/Expression-of-BLyS-and-its-receptors-in-Bcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,15]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-02-0762","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,15]]}}}